Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.1 USD | +1.39% | +19.96% | +14.64% |
18/04 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
10/04 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Business Summary
Number of employees: 72
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 01/15/01 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 01/20/01 |
Peter García
DFI | Director of Finance/CFO | 62 | 01/20/01 |
Chief Tech/Sci/R&D Officer | - | 01/21/01 | |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/16/01 |
Michael Chang
COO | Chief Operating Officer | - | 01/15/01 |
Shelly Pinto
AUD | Comptroller/Controller/Auditor | 48 | 03/21/03 |
Hong I. Wan
PRN | Corporate Officer/Principal | - | 01/15/01 |
Hank Stern
PRN | Corporate Officer/Principal | - | 01/15/01 |
Chris Byrd
LAW | General Counsel | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 28/22/28 |
Corey Goodman
CHM | Chairman | 72 | 01/15/01 |
Jack Nielsen
BRD | Director/Board Member | 60 | 01/20/01 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 01/20/01 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 01/20/01 |
Jaume Pons
FOU | Founder | 58 | 01/15/01 |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/16/01 |
Itziar Canamasas
BRD | Director/Board Member | 50 | 11/22/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,498,816 | 39,460,945 ( 78.14 %) | 0 | 78.14 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.64% | 851M | |
-2.33% | 103B | |
+1.94% | 95.28B | |
+1.46% | 22.15B | |
-15.29% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-12.85% | 16.05B | |
+4.36% | 13.68B | |
+35.54% | 12.17B |
- Stock Market
- Equities
- ALXO Stock
- Company ALX Oncology Holdings Inc.